N2N Technologies Limited has made a regulatory disclosure pursuant to Regulation 30 read with Para A(7) of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Board of Directors at its meeting held on November 02, 2026, considered and approved the following management appointments:
1. Appointment of Chief Executive Officer (CEO)
- Mr. Mehul Parekh appointed as Chief Executive Officer (CEO)
- Effective from November 02, 2026
- Brief profile: Distinguished pharmaceutical industry professional with over 40 years of experience. Previously served as Managing Director of a reputed pharmaceutical company engaged in the manufacture and export of Active Pharmaceutical Ingredients (APIs).
- Currently appointed as a Director of the Company
2. Appointment of Chief Financial Officer (CFO)
- Mr. Firoze Kapadia appointed as Chief Financial Officer (CFO)
- Effective from November 02, 2026
- Brief profile: Engaged in agro commodities business operating in West Africa. Has a strong background in agribusiness, strategic planning, and operational management.
- Currently appointed as a Director of the Company
Meeting Details
- The Board meeting commenced at 5:30 pm and concluded at 6:15 pm on November 02, 2026
- The disclosure references SEBI Circular dated July 13, 2023
Additional Information
- Both appointments represent new appointments (not replacements)
- The disclosure was signed by Rakesh Kankariya, Company Secretary, on November 02, 2026 at 18:47:43 +05'30'
- The company has provided the required profiles and details as per Annexure A